- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/52 - Purines, e.g. adenine
Patent holdings for IPC class A61K 31/52
Total number of patents in this class: 2841
10-year publication summary
|
173
|
196
|
196
|
179
|
187
|
179
|
147
|
166
|
151
|
135
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10686 |
49 |
| The Regents of the University of California | 20172 |
44 |
| Gilead Sciences, Inc. | 2063 |
30 |
| Infinity Pharmaceuticals, Inc. | 100 |
28 |
| Merck Sharp & Dohme LLC | 3732 |
28 |
| Boehringer Ingelheim International GmbH | 4641 |
25 |
| Merck Sharp & Dohme Corp. | 2190 |
24 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2890 |
24 |
| Signal Pharmaceuticals, LLC | 181 |
23 |
| Dana-Farber Cancer Institute, Inc. | 2604 |
22 |
| F. Hoffmann-La Roche AG | 7942 |
21 |
| Epizyme, Inc. | 374 |
21 |
| K36 Therapeutics, Inc. | 24 |
21 |
| Amgen Inc. | 4129 |
20 |
| The Johns Hopkins University | 5734 |
20 |
| Intellikine LLC | 42 |
19 |
| Centre National de La Recherche Scientifique | 10611 |
18 |
| Rhizen Pharmaceuticals AG | 55 |
18 |
| AstraZeneca AB | 2854 |
17 |
| Incyte Corporation | 1032 |
17 |
| Other owners | 2352 |